Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Langmuir : the ACS Journal of Surfaces and Colloids|December 14, 2016
Chemical Identification at the Solid-Liquid InterfaceHagen Söngen, Christoph Marutschke, Peter Spijker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancerHerbert I Hurwitz, Louis Fehrenbacher, John D Hainsworth, et al.
Journal of the National Cancer Institute|August 10, 2007
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabFrank A Scappaticci, Jamey R Skillings, Scott N Holden, et al.
Future Oncology (London, England)|September 28, 2020
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphomaMartin Dreyling, Constantine S Tam, Michael Wang, et al.
The New England Journal of Medicine|June 4, 2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerHerbert Hurwitz, Louis Fehrenbacher, William Novotny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
Pageof 3